Recombinant Zoster Vaccine

BIOLOGICAL6 trials

Sponsors

RenJi Hospital, Calmy Alexandra, Prof Patrice Lalive, Wuhan BravoVax Co., Ltd., Ann & Robert H Lurie Children's Hospital of Chicago

Conditions

Herpes ZosterRZV Vaccine (Shingrix ®)Recombinant Zoster VaccineShinglesSystemic Lupus ErythematosusVaricella ZosterZoster

Phase 1

Phase I Clinical Trial of a Candidate Herpes Zoster Vaccine

Wuhan BravoVax Co., Ltd.Herpes Zoster

Start: 2023-08-01End: 2024-07-31Target: 40Updated: 2023-02-08

Phase 4

Immune Response of Shingrix Vaccine in People Living With HIV (> 50 y.o.) Compared to Age-matched Controls

Active, not recruitingNCT05575830

Calmy AlexandraRZV Vaccine (Shingrix ®)

Start: 2022-12-14End: 2026-03-31Target: 225Updated: 2025-09-05

Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients

RecruitingNCT05596526

Prof Patrice LaliveShingles, Zoster

Start: 2022-12-01End: 2025-12-31Target: 100Updated: 2024-04-10

Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients

Enrolling by invitationNCT06162494

Ann & Robert H Lurie Children's Hospital of ChicagoVaricella Zoster

Start: 2024-03-18End: 2028-09-30Target: 80Updated: 2026-03-27

A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland

RecruitingNCT07502560

GlaxoSmithKlineHerpes Zoster

Start: 2026-03-31End: 2037-03-31Target: 33609Updated: 2026-05-12

Unknown Phase

Recombinant Zoster Vaccine in Stable SLE Patients

RenJi HospitalHerpes Zoster, Recombinant Zoster Vaccine, Systemic Lupus Erythematosus

Start: 2021-04-20End: 2023-09-30Target: 464Updated: 2022-10-26

Related Papers

Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR'HIV): a multicenter, international, non-randomized clinical trial study protocol.

2024-03-192 citations